Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 268
Filter
Add more filters

Complementary Medicines
Publication year range
1.
J Ethnopharmacol ; 321: 117489, 2024 Mar 01.
Article in English | MEDLINE | ID: mdl-38012973

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Litsea glaucescens K. (Lauraceae) is a small tree from the Mexican and Central American temperate forests, named as "Laurel". Its aromatic leaves are ordinarily consumed as condiments, but also are important in Mexican Traditional Medicine, and among the most important non wood forest products in this area. The leaves are currently used in a decoction for the relief of sadness by the Mazahua ethnic group. Interestingly, "Laurel" has a long history. It was named as "Ehecapahtli" (wind medicine) in pre-Columbian times and applied to heal maladies correlated to the Central Nervous System, among them depression, according to botanical texts written in the American Continent almost five centuries ago. AIM OF THE STUDY: Depression is the first cause of incapacity in the world, and society demands alternative treatments, including aromatherapy. We have previously demonstrated the antidepressant-like activity of L. glaucescens leaves' essential oil (LEO), as well as their monoterpenes linalool, and beta-pinene by intraperitoneal route in a mice behavioral model. Here we now examined if LEO and linalool exhibit this property and anxiolytic activity when administered to mice by inhalation. We also investigated if these effects occur by BDNF pathway activation in the brain. MATERIALS AND METHODS: The LEO was prepared by distillation with water steam and analyzed by gas chromatography-mass spectrometry (GC-MS). The monoterpenes linalool, eucalyptol and ß-pinene were identified and quantified. Antidepressant type properties were determined with the Forced Swim Test (FST) on mice previously exposed to LEO or linalool in an inhalation chamber. The spontaneous locomotor activity and the sedative effect were assessed with the Open Field Test (OFT), and the Exploratory Cylinder (EC), respectively. The anxiolytic properties were investigated with the Elevated Plus Maze Apparatus (EPM) and the Hole Board Test (HBT). All experiments were video documented. The mice were subjected to euthanasia, and the brain hippocampus and prefrontal cortex were dissected. RESULTS: The L. glaucescens essential oil (LEO) contains 31 compounds according to GC/MS, including eucalyptol, linalool and beta-pinene. The LEO has anxiolytic effect by inhalation in mice, as well as linalool, and ß-pinene, as indicated by OFT and EC tests. The LEO and imipramine have antidepressant like activity in mice as revealed by the FST; however, linalool and ketamine treatments didn't modify the time of immobility. The BDNF was increased in FST in mice treated with LEO in both areas of the brain as revealed by Western blot; but did not decrease the level of corticosterone in plasma. The OFT indicated that LEO and imipramine didn't reduce the spontaneous motor activity, while linalool and ketamine caused a significant decrease. CONCLUSION: Here we report by the first time that L. glaucescens leaves essential oil has anxiolytic effect by inhalation in mice, as well as linalool, and ß-pinene. This oil also maintains its antidepressant-like activity by this administration way, similarly to the previously determined intraperitoneally. Since inhalation is a common administration route for humans, our results suggest L. glaucescens essential oil deserve future investigation due to its potential application in aromatherapy.


Subject(s)
Anti-Anxiety Agents , Ketamine , Lauraceae , Litsea , Oils, Volatile , Humans , Mice , Animals , Anti-Anxiety Agents/pharmacology , Anti-Anxiety Agents/therapeutic use , Oils, Volatile/chemistry , Brain-Derived Neurotrophic Factor , Imipramine/pharmacology , Eucalyptol/pharmacology , Ketamine/pharmacology , Antidepressive Agents/pharmacology , Antidepressive Agents/therapeutic use , Antidepressive Agents/chemistry , Monoterpenes/pharmacology , Behavior, Animal
2.
Neuroscience ; 519: 90-106, 2023 05 21.
Article in English | MEDLINE | ID: mdl-36948482

ABSTRACT

Iron supplementation previously demonstrated antidepressant-like effects in post-partum rats. The present study evaluates the possible synergistic antidepressant effect of sub-therapeutic dose of iron co-administered with citalopram or imipramine in female Institute of Cancer Research mice. Depression-like symptoms were induced in the forced swim (FST), tail suspension (TST), and open space swim (OSST) tests while open field test (OFT) was used to assess locomotor activity. Mice (n = 8) received iron (0.8-7.2 mg/kg), citalopram (3-30 mg/kg), imipramine (3-30 mg/kg), desferrioxamine (50 mg/kg) or saline in the single treatment phase of each model and subsequently a sub-therapeutic dose of iron co-administered with citalopram or imipramine. Assessment of serum brain derived neurotrophic factor (BDNF) and dendritic spine density was done using ELISA and Golgi staining techniques respectively. Iron, citalopram and imipramine, unlike desferrioxamine, reduced immobility score in the TST, FST and OSST without affecting locomotor activity, suggesting antidepressant-like effect. Sub-therapeutic dose of iron in combination with citalopram or imipramine further enhanced the antidepressant-like effect, producing a more rapid effect when compared to the iron, citalopram or imipramine alone. Iron, citalopram and imipramine or their combinations increased serum BDNF concentration, hippocampal neuronal count and dendritic spine densities. Our study provides experimental evidence that iron has antidepressant-like effect and sub-therapeutic dose of iron combined with citalopram or imipramine produces more rapid antidepressant-like effect. We further show that iron alone or its combination with citalopram or imipramine attenuates the neuronal loss associated with depressive conditions, increases dendritic spines density and BDNF levels. These finding suggest iron-induced neuronal plasticity in the mice brain.


Subject(s)
Citalopram , Imipramine , Female , Mice , Rats , Animals , Imipramine/pharmacology , Imipramine/therapeutic use , Citalopram/pharmacology , Brain-Derived Neurotrophic Factor/metabolism , Dendritic Spines/metabolism , Deferoxamine/pharmacology , Antidepressive Agents/pharmacology , Antidepressive Agents/therapeutic use , Swimming , Hippocampus/metabolism , Depression/drug therapy
3.
Molecules ; 27(22)2022 Nov 13.
Article in English | MEDLINE | ID: mdl-36431928

ABSTRACT

Medicinal plants belonging to the Verbenaceae family demonstrated antidepressant effects in preclinical studies. Depression is one of the largest contributors to the global health burden of all countries. Plants from the Aloysia genus are traditionally used for affective disorders, and some of them have proven anxiolytic and antidepressant activity. The aim of this work was to evaluate the antidepressant effect of the ethanolic extract of Aloysia gratissima var. gratissima (Agg) and Aloysia virgata var. platyphylla (Avp) in mice. A tail suspension test (TST) and forced swimming test (FST) were conducted after three doses in a period of 24 h and after 7 days of treatment. Imipramine was used as an antidepressant drug. The main results demonstrated that Agg extract reduced the immobility time in mice treated orally for 7 consecutive days when compared to the control group (reduced by about 77%, imipramine 70%). Animals treated with three doses of Avp in a 24-h period had reduced immobility time in the FST (60%), and after 7 days of treatment the reduction was greater (Avp 50, 100, and 200 about 85%; Avp 400, 96.5%; p < 0.0001, imipramine, 77%). LCMS analysis showed the presence of verbascoside, hoffmaniaketone, and hoffmaniaketone acetate in both, A. virgata var. platyphylla and A. gratissima var gratissima. The flavonoids nepetin and 6-hydroxyluteolin were also found in Agg. Both tested extracts demonstrated promising antidepressant-like activity in mice.


Subject(s)
Ethanol , Verbenaceae , Mice , Animals , Imipramine/pharmacology , Plant Extracts/therapeutic use , Verbenaceae/chemistry , Antidepressive Agents/pharmacology , Antidepressive Agents/therapeutic use
4.
Environ Sci Pollut Res Int ; 29(18): 27172-27181, 2022 Apr.
Article in English | MEDLINE | ID: mdl-34981394

ABSTRACT

The present study was conducted to evaluate the effect of Cochlospermum religiosum (CSR) in animal models of depression and anxiety. The CSR leaves are well known for their sedative, antibacterial, antifungal antioxidant, memory enhancing, anxiolytic and antidepressant potential. In present study, the extract of the leaves is used to relieve the anxiolytic and antidepressant potential. The leaves of CSR were investigated for antidepressant and anxiolytic activities in mice behavioural models namely, spontaneous locomotor activity (SLA), forced swim test (FST), tail suspension test (TST), elevated plus maze (EPM) and marble burying behaviour (MBB). The mechanism was supported by reserpine-induced hypothermia (RIH). Further, the in vivo synergistic evaluation of the CSR leaf extract was evaluated with imipramine and fluoxetine. The treatment of mice with ethanolic extract of CSR leaves for 7 days resulted significant antidepressant and anxiolytic effects (p < 0.05 for 50 mg/Kg p.o / p < 0.01 for 100 mg/kg p.o) with null impact on baseline locomotor activity. Further, the study on rat RIH model revealed that the CSR (50 mg/kg p.o) predominantly antagonized the effect (p < 0.05) of reserpine. Furthermore, synergic action was screened by co-administration of leaf extracts of CSR with fluoxetine (10 mg/Kg, i.p.) and imipramine (10 mg/Kg, i.p.) at below therapeutic dose levels using FST, TST, EPM and MBB. The synergistic effect was significant (p < 0.05) for both antidepressant and anxiolytic activities as compared to therapeutic doses of extract, imipramine and fluoxetine.


Subject(s)
Anti-Anxiety Agents , Animals , Anti-Anxiety Agents/pharmacology , Anti-Anxiety Agents/therapeutic use , Antidepressive Agents/pharmacology , Behavior, Animal , Bixaceae , Depression/drug therapy , Fluoxetine/pharmacology , Imipramine/pharmacology , Mice , Motor Activity , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Rats , Reserpine/pharmacology
5.
Neurosci Lett ; 760: 136095, 2021 08 24.
Article in English | MEDLINE | ID: mdl-34216716

ABSTRACT

Imipramine is a tricyclic antidepressant (TCA) drug that is sometimes used to treat neuropathic pain. Citicoline is a dietary supplement that has been used as a neuroprotective agent for neurological disorders. Probable interaction between imipramine and citicoline on pain and depression behaviors was examined in mice using a tail-flick test, open field test (OFT), forced swimming test (FST), and tail suspension test (TST). The results indicated that the intraperitoneal (i.p.) administration of citicoline (50 mg/kg) induced analgesic and antidepressant-like behaviors in mice. Similarly, i.p. injection of imipramine (5 mg/kg) induced dose-dependent anti-nociceptive and anti-depressive effects. Co-administration of different doses of imipramine (1.25, 2.5, and 5 mg/kg) along with an ineffective dose of citicoline (6.25 mg/kg) increased tail-flick latency and decreased immobility time in the FST, suggesting an analgesic and antidepressant-like behaviors. Interestingly, there is a synergistic effect between imipramine and citicoline upon the induction of analgesic and antidepressant effects. All doses of the drugs had no significant effect on the locomotor activity. Based on these results, it can be concluded that the administration of citicoline (as an adjuvant drug) in combination with imipramine increased the efficacy of TCA drugs for modulation of pain and depression behaviors.


Subject(s)
Cytidine Diphosphate Choline/pharmacology , Depression/drug therapy , Imipramine/pharmacology , Pain/drug therapy , Analgesics/pharmacology , Analgesics/therapeutic use , Animals , Antidepressive Agents, Tricyclic/pharmacology , Antidepressive Agents, Tricyclic/therapeutic use , Cytidine Diphosphate Choline/therapeutic use , Depression/etiology , Disease Models, Animal , Drug Synergism , Humans , Imipramine/therapeutic use , Injections, Intraperitoneal , Male , Mice , Nociception/drug effects
6.
Pharmacopsychiatry ; 54(1): 37-46, 2021 Jan.
Article in English | MEDLINE | ID: mdl-33254260

ABSTRACT

BACKGROUND: Silexan, a special essential oil from flowering tops of lavandula angustifolia, is used to treat subsyndromal anxiety disorders. In a recent clinical trial, Silexan also showed antidepressant effects in patients suffering from mixed anxiety-depression (ICD-10 F41.2). Since preclinical data explaining antidepressant properties of Silexan are missing, we decided to investigate if Silexan also shows antidepressant-like effects in vitro as well as in vivo models. METHODS: We used the forced swimming test (FST) in rats as a simple behavioral test indicative of antidepressant activity in vivo. As environmental events and other risk factors contribute to depression through converging molecular and cellular mechanisms that disrupt neuronal function and morphology-resulting in dysfunction of the circuitry that is essential for mood regulation and cognitive function-we investigated the neurotrophic properties of Silexan in neuronal cell lines and primary hippocampal neurons. RESULTS: The antidepressant activity of Silexan (30 mg/kg BW) in the FST was comparable to the tricyclic antidepressant imipramine (20 mg/kg BW) after 9-day treatment. Silexan triggered neurite outgrowth and synaptogenesis in 2 different neuronal cell models and led to a significant increase in synaptogenesis in primary hippocampal neurons. Silexan led to a significant phosphorylation of protein kinase A and subsequent CREB phosphorylation. CONCLUSION: Taken together, Silexan demonstrates antidepressant-like effects in cellular as well as animal models for antidepressant activity. Therefore, our data provides preclinical evidence for the clinical antidepressant effects of Silexan in patients with mixed depression and anxiety.


Subject(s)
Antidepressive Agents/pharmacology , Oils, Volatile/pharmacology , Plant Oils/pharmacology , Animals , CREB-Binding Protein/metabolism , Cell Culture Techniques , Cyclic AMP-Dependent Protein Kinases/metabolism , Dose-Response Relationship, Drug , Imipramine/pharmacology , Lavandula , Pregabalin/pharmacology , Rats , Rats, Sprague-Dawley
7.
Biomed Res Int ; 2020: 1507561, 2020.
Article in English | MEDLINE | ID: mdl-33015153

ABSTRACT

OBJECTIVE: This study was aimed at observing the effect Jiao-Tai-Wan in menopausal depression. METHODS: In this paper, we used ovariectomized mice subjected to chronic unpredictable stress as a menopausal depression model. After the chronic stress, mice were administrated with JTW (3.3 and 6.6mg/kg) and imipramine (10 mg/kg) for 14 days. On the 14th day, mice were subjected to the behavior test like the forced swim test, tail suspension test, and locomotor activity or were sacrificed to assess the protein changes in different brain regions. RESULTS: The administration of JTW at doses of 3.3 and 6.6mg/kg (p.o.) significantly shortened the duration of immobility in forced swim and tail suspension tests. There was no obvious difference in locomotor activity among all the groups. The western blot analysis data indicated that treatment with JTW (3.3 and 6.6 mg/kg, p.o.) prominently increased the A1R protein and the downstream protein ERK1/2 levels in the prefrontal cortex and hippocampus. However, the administration of JTW did not influence c-Fos protein in either the prefrontal cortex or hippocampus. CONCLUSION: Our findings suggest that JTW plays a vital role in ameliorating menopausal depression symptoms in the A1R-ERK1/2 pathway in the prefrontal cortex and hippocampus.


Subject(s)
Behavior, Animal/drug effects , Depression/drug therapy , Depressive Disorder/drug therapy , Drugs, Chinese Herbal/pharmacology , Stress, Psychological/drug therapy , Animals , Depression/metabolism , Depressive Disorder/metabolism , Disease Models, Animal , Female , Hindlimb Suspension/physiology , Hippocampus/drug effects , Hippocampus/metabolism , Imipramine/pharmacology , Locomotion/drug effects , MAP Kinase Signaling System/drug effects , Mice , Mice, Inbred ICR , Ovariectomy/methods , Prefrontal Cortex/drug effects , Prefrontal Cortex/metabolism , Stress, Psychological/metabolism , Swimming/physiology
8.
Nutrients ; 12(9)2020 Aug 20.
Article in English | MEDLINE | ID: mdl-32825449

ABSTRACT

Zinc (Zn) was found to enhance the antidepressant efficacy of imipramine (IMI) in human depression and animal tests/models of depression. However, the underlying mechanism for this effect remains unknown. We measured the effect of intragastric (p.o.) combined administration of IMI (60 mg/kg) and Zn (40 mg Zn/kg) in the forced swim test (FST) in mice. The effect of Zn + IMI on serum, brain, and intestinal Zn concentrations; Zn transporter (ZnT, ZIP) protein levels in the intestine and ZnT in the brain; including BDNF (brain-derived neurotrophic factor) and CREB (cAMP response element-binding protein) protein levels in the brain were evaluated. Finally, the effect of IMI on Zn permeability was measured in vitro in colon epithelial Caco-2 cells. The co-administration of IMI and Zn induced antidepressant-like activity in the FST in mice compared to controls and Zn or IMI given alone. This effect correlated with increased BDNF and the ratio of pCREB/CREB protein levels in the prefrontal cortex (PFC) compared to the control group. Zn + IMI co-treatment increased Zn concentrations in the serum and brain compared to the control group. However, in serum, co-administration of IMI and Zn decreased Zn concentration compared to Zn alone treatment. Also, there was a reduction in the Zn-induced enhancement of ZnT1 protein level in the small intestine. Zn + IMI also induced an increase in the ZnT4 protein level in the PFC compared to the control group and normalized the Zn-induced decrease in the ZnT1 protein level in the hippocampus (Hp). The in vitro studies revealed enhanced Zn permeability (observed as the increased transfer of Zn through the intestinal cell membrane) after IMI treatment. Our data indicate that IMI enhances Zn transfer through the intestinal tract and influences the redistribution of Zn between the blood and brain. These mechanisms might explain the enhanced antidepressant efficacy of combined IMI/Zn treatment observed in the FST in mice.


Subject(s)
Antidepressive Agents, Tricyclic/pharmacology , Brain/metabolism , Imipramine/pharmacology , Zinc/metabolism , Zinc/pharmacology , Administration, Oral , Animals , Antidepressive Agents, Tricyclic/administration & dosage , Brain-Derived Neurotrophic Factor/metabolism , Caco-2 Cells , Carrier Proteins/metabolism , Cation Transport Proteins/metabolism , Cyclic AMP Response Element-Binding Protein/metabolism , Drug Synergism , Gastrointestinal Tract/metabolism , Humans , Imipramine/administration & dosage , Male , Mice , Zinc/administration & dosage , Zinc/blood
9.
Libyan J Med ; 15(1): 1725991, 2020 Dec.
Article in English | MEDLINE | ID: mdl-32048914

ABSTRACT

Background: The flowering parts of Gentiana olivieri, known as 'Afat' in the southeastern Anatolia region of Turkey, are used as a tonic, an appetizer, and for the treatment of several mental disorders, including depression. The purpose of this study is to investigate the antidepressant effect of G. olivieri ethanol extract (GOEE) in a chronic mild stress-induced rat model, which was used to mimic a depressive state in humans, and to compare the effect with that of imipramine.Methods: Male Sprague-Dawley rats were randomly divided into six groups: control, stress, treated with imipramine (positive control) and treated with GOEE at three different (200, 500, 1000 mg/kg) doses groups. The rats in all groups, except the control group, were exposed to chronic mild stress. At the end of the 3-week experimental period, biochemical and behavioral parameters were examined.Results: The results showed that treatment with GOEE or imipramine significantly improved rats' sucrose consumption which was diminished by chronic mild stress, restored serum levels of corticosterone and proinflammatory cytokines (interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α)), prevented the increase of liver index of rats. Moreover, in the hippocampus tissue, decreased serotonin and noradrenaline levels were significantly increased by treatment with GOEE or imipramine, and antioxidant parameters (thiobarbituric acid reactive substances (TBARS), superoxide dismutase (SOD), and glutathione (GSH)) were significantly improved by treatment with GOEE though not with imipramine.Conclusion: The data demonstrate that G. olivieri may exert its antidepressant activity by improving monoaminergic system disorders, and by favorably affecting the antioxidant, inflammatory and the endocrine mechanisms.


Subject(s)
Depression/drug therapy , Gentiana/adverse effects , Medicine, Traditional/adverse effects , Plant Extracts/pharmacology , Stress, Psychological/drug therapy , Animals , Antidepressive Agents, Tricyclic/pharmacology , Antioxidants/pharmacology , Case-Control Studies , Corticosterone/blood , Cytokines/blood , Cytokines/drug effects , Hippocampus/drug effects , Humans , Imipramine/pharmacology , Liver/drug effects , Male , Rats , Rats, Sprague-Dawley , Tumor Necrosis Factor-alpha/blood , Tumor Necrosis Factor-alpha/drug effects
10.
Arch Physiol Biochem ; 126(2): 95-100, 2020 May.
Article in English | MEDLINE | ID: mdl-30169970

ABSTRACT

This study investigated the effects of garlic on anxiety- and depression-related behaviors and brain oxidative markers in streptozotocin (STZ)-induced diabetes in rats. Fifty-six male Wistar rats were randomly divided into seven experimental groups (n = 8/group): control, diabetic + saline, diabetic + garlic, diabetic + imipramine, and diabetic + diazepam groups. Animals received garlic homogenate (0.1, 0.25, and 0.5 g/kg) for 10 days. At the end of the treatments, anxiety- and depressive-related behaviors were evaluated by elevated plus maze (EPM) and forced swimming test (FST), respectively. Superoxide dismutase (SOD) and glutathione peroxidase (GPx) activities and malondialdehyde (MDA) levels were measured in the brain. Diabetic + garlic (0.5 g/kg) group showed lower anxiety- and- depressive-like behaviors as compared to the diabetic rats. Furthermore, garlic treatment (0.5 g/kg) attenuated MDA levels and enhanced SOD and GPx activities in the brain. Our findings indicate that garlic alleviates anxiety- and depression-related behaviors in the diabetic rats possibly by attenuation of brain oxidative stress.


Subject(s)
Antidepressive Agents/pharmacology , Antioxidants/pharmacology , Anxiety/prevention & control , Depressive Disorder/prevention & control , Garlic/chemistry , Plant Extracts/pharmacology , Stress, Psychological/prevention & control , Animals , Anxiety/complications , Anxiety/metabolism , Anxiety/physiopathology , Brain/drug effects , Brain/metabolism , Depressive Disorder/complications , Depressive Disorder/metabolism , Depressive Disorder/physiopathology , Diabetes Mellitus, Experimental/chemically induced , Diabetes Mellitus, Experimental/complications , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Experimental/physiopathology , Diazepam/pharmacology , Glutathione Peroxidase/metabolism , Imipramine/pharmacology , Male , Malondialdehyde/antagonists & inhibitors , Malondialdehyde/metabolism , Maze Learning/drug effects , Oxidative Stress/drug effects , Rats , Rats, Wistar , Streptozocin , Stress, Psychological/complications , Stress, Psychological/metabolism , Stress, Psychological/physiopathology , Superoxide Dismutase/metabolism , Swimming
11.
Acta Pharmacol Sin ; 41(5): 650-660, 2020 May.
Article in English | MEDLINE | ID: mdl-31848475

ABSTRACT

Leptin resistance in endothelial cells leads to vascular endothelial dysfunction, which is the beginning and crucial link of atherosclerosis. However, the mechanism of leptin resistance remains obscure. Acid sphingomyelinase (ASM) catalyzes the hydrolysis of sphingomyelin to produce ceramide, which plays an important role in the progression of metabolic and cardiovascular diseases. In this study, we investigated whether ASM could regulate leptin resistance in vascular endothelial cells. We induced endothelial leptin resistance in rat aortic endothelial cells through treatment with palmitic acid (0.3 mM) or knockdown of leptin receptor (Ob-Rb), which resulted in the increase of suppressor of cytokine signaling 3 expression, the decrease of Ob-Rb expression, and signal transducer and activator of transcription 3 (STAT3) phosphorylation at Tyr705. We found that these indicators of leptin resistance were reversed by knockdown of ASM or by the selective ASM inhibitors amitriptyline (AMI) and imipramine (IMI). Supplementation of ceramide inhibited Ob-Rb expression and STAT3 phosphorylation by inhibiting extracellular signal-regulated kinase 1/2 activation. Furthermore, we found that knockdown of ASM enhanced endothelial nitric oxide (NO) synthase activity and NO production, as well as the Akt phosphorylation at ser473, which was regulated by STAT3. High-fat diet (HFD) feeding-induced leptin resistance in rats in vivo; administration of AMI and IMI (10 mg· kg-1 per day, intraperitoneally, for 2 weeks) increased the release of endothelial NO to relieve the vasodilatory response and improved the endothelial leptin resistance in the aorta of HFD-fed rats. These results suggest that ASM downregulation reverses endothelial leptin resistance, and consequently improves vascular endothelial dysfunction. This study highlighted ASM as a potential therapeutic target for endothelial leptin resistance.


Subject(s)
Down-Regulation , Endothelial Cells/metabolism , Leptin/metabolism , Sphingomyelin Phosphodiesterase/metabolism , Amitriptyline/pharmacology , Animals , Biocatalysis , Cells, Cultured , Disease Models, Animal , Down-Regulation/drug effects , Endothelial Cells/drug effects , Enzyme Inhibitors/pharmacology , Imipramine/pharmacology , Leptin/antagonists & inhibitors , Male , Palmitic Acid/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, Leptin/deficiency , Receptors, Leptin/metabolism , Sphingomyelin Phosphodiesterase/antagonists & inhibitors
12.
PLoS One ; 14(6): e0218923, 2019.
Article in English | MEDLINE | ID: mdl-31251788

ABSTRACT

Although algae have been the focal point of biofuel research, studies on their biological activities have been limited. In recent years, however, the importance of algae as sources of functional ingredients has been recognized due to their health beneficial effects. In this study, we evaluated the antidepressant-like activities of ethanol extract of Aurantiochytrium sp. (EEA) in the forced swimming test (FST)-induced depression in ICR mice. Imipramine, a commercially available tricyclic antidepressant drug, was used as positive control. Animals were administered EEA orally for 14 consecutive days and were subjected to the locomotor activity testing. Additionally, changes in gene expression in mice brain were assessed by real-time PCR and microarray assays to understand the molecular mechanisms underlying the effect of EEA. We found that the immobility time in FST was significantly reduced in the EEA-treated mice compared to that of in the control mice. Microarray and real-time PCR results revealed that EEA treatment induced changes in several genes in mice brain associated with pro-inflammation and dopaminergic, cholinergic, glutamatergic, and serotonergic synapses. It has previously been reported that several cytokines, such as IL-6 and TNF-α, which mediate neuroinflammation, are also responsible for indirectly altering brain neurotransmitter levels in neuropsychiatric disorders. Therefore, the regulation of the expression of pro-inflammatory genes in EEA-administered mice brain is considered to contribute to the enhancement of neurotransmitter systems-related gene expression in our study. Moreover, our in vitro study suggested that squalene, a component produced by Aurantiochytrium, was one of the active substances in EEA. In conclusion, our study provides the first evidence that Aurantiochytrium sp. can reduce neuroinflammation that may contribute to the modulation of the neurotransmitter systems, which could underlie its antistress and antidepressant effects.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Antidepressive Agents/pharmacology , Behavior, Animal/drug effects , Microalgae , Plant Extracts/pharmacology , Squalene/pharmacology , Animals , Anti-Inflammatory Agents/therapeutic use , Antidepressive Agents/therapeutic use , Brain/drug effects , Brain/metabolism , Brain-Derived Neurotrophic Factor/genetics , Brain-Derived Neurotrophic Factor/metabolism , Cell Line, Tumor , Cytokines/metabolism , Depression/drug therapy , Depression/metabolism , Gene Expression/drug effects , Humans , Imipramine/pharmacology , Interleukin-6/genetics , Interleukin-6/metabolism , Male , Mice , Mice, Inbred ICR , Squalene/therapeutic use , Swimming , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/metabolism
13.
Behav Brain Res ; 364: 274-280, 2019 05 17.
Article in English | MEDLINE | ID: mdl-30738101

ABSTRACT

Depression is associated with dysregulation of methyl group metabolism such as low S-adenosylmethionine (SAM). We previously reported that Flinders Sensitive Line (FSL) rats, an animal model of depression, had lower concentrations of liver SAM than the control rats, Flinders Resistant Line (FRL) rats. The present study investigated if SAM supplementation may correct liver SAM and behavioral abnormalities in this model. Moreover, we compared one-carbon (C1) metabolites, neurotransmitters, and gastrointestinal (GI) transit in SAM-treated versus imipramine (IMI)-treated animals. FSL rats received vehicle, IMI, SAM, or IMI + SAM (n = 9-10 per group) once daily through oral gavage for 4 weeks; FRL rats received vehicle. Behavior was assessed using standard tests for locomotion, cognition, and depressive-like behavior. Monoamine neurotransmitters and C1 metabolites were measured using UHPLC-ECD and UPLC-MS/MS, respectively. Compared to FRL rats, FSLs had lower liver SAM, higher plasma serotonin, lower hippocampal dopamine and serotonin turnover, and faster GI transit. Behaviorally, FSL rats showed impaired cognitive performance as well as increased depressive-like behavior compared to FRLs. Coadministration of IMI and SAM seemed to have adverse effects on spatial memory. SAM or IMI administration did not reverse C1 metabolites, neurotransmitters, or GI transit in FSLs. Despite low liver SAM in FSL rats, orally administered SAM did not show antidepressant effects in this specific animal model of depression.


Subject(s)
Depression/metabolism , Imipramine/pharmacology , S-Adenosylmethionine/pharmacology , Animals , Antidepressive Agents/pharmacology , Brain/metabolism , Cognition/drug effects , Depression/drug therapy , Depression/physiopathology , Depressive Disorder/drug therapy , Depressive Disorder/metabolism , Disease Models, Animal , Dopamine/metabolism , Hippocampus/metabolism , Imipramine/metabolism , Male , Rats , Rats, Inbred Strains , S-Adenosylmethionine/metabolism , Serotonin/metabolism , Spatial Memory/drug effects
14.
Br J Pharmacol ; 175(18): 3640-3655, 2018 09.
Article in English | MEDLINE | ID: mdl-29953580

ABSTRACT

BACKGROUND AND PURPOSE: Macropinocytosis is involved in many pathologies, including cardiovascular disorders, cancer, allergic diseases, viral and bacterial infections. Unfortunately, the currently available pharmacological inhibitors of macropinocytosis interrupt other endocytic processes and have non-specific endocytosis-independent effects. Here we have sought to identify new, clinically relevant inhibitors of macropinocytosis, using an FDA-approved drug library. EXPERIMENTAL APPROACH: In the present study, 640 FDA-approved compounds were tested for their ability to inhibit macropinocytosis. A series of secondary assays were performed to confirm inhibitory activity, determine IC50 values and investigate cell toxicity. The ability of identified hits to inhibit phagocytosis and clathrin-mediated and caveolin-mediated endocytosis was also investigated. Scanning electron microscopy and molecular biology techniques were utilized to examine the mechanisms by which selected compounds inhibit macropinocytosis. KEY RESULTS: The primary screen identified 14 compounds that at ~10 µM concentration inhibit >95% of macropinocytotic solute internalization. Three compounds - imipramine, phenoxybenzamine and vinblastine - potently inhibited (IC50  ≤ 131 nM) macropinocytosis without exerting cytotoxic effects or inhibiting other endocytic pathways. Scanning electron microscopy imaging indicated that imipramine inhibits membrane ruffle formation, a critical early step leading to initiation of macropinocytosis. Finally, imipramine has been shown to inhibit macropinocytosis in several cell types, including cancer cells, dendritic cells and macrophages. CONCLUSIONS AND IMPLICATIONS: Our results identify imipramine as a new pharmacological tool to study macropinocytosis in cellular and biological systems. This study also suggests that imipramine could be a good candidate for repurposing as a therapeutic agent in pathological processes involving macropinocytosis.


Subject(s)
Drug Approval/legislation & jurisprudence , Pinocytosis/drug effects , Animals , Cell Line, Tumor , Cell Membrane/drug effects , Clathrin/metabolism , Dendritic Cells/drug effects , Drug Evaluation, Preclinical , Endocytosis , Enzyme Activation/drug effects , Flow Cytometry , Humans , Imipramine/pharmacology , Inhibitory Concentration 50 , Macrophages/drug effects , Male , Mice , Mice, Inbred C57BL , Phagocytosis , RAW 264.7 Cells , Reactive Oxygen Species/metabolism , Signal Transduction/drug effects , United States , United States Food and Drug Administration
15.
Pharm Biol ; 56(1): 245-252, 2018 Dec.
Article in English | MEDLINE | ID: mdl-29569964

ABSTRACT

CONTEXT: Depression is an inflammatory, commonly occurring and lethal psychiatric disorder having high lifetime prevalence. Zanthoxylum alatum Roxb. (Rutaceae), commonly called Timur, has high medicinal value and is used ethnomedicinally for the treatment of various diseases. OBJECTIVE: To evaluate the effect of hexane extract of Z. alatum seeds (ZAHE) on lipopolysaccharide (LPS)-induced depression-like behaviour in Swiss albino mice. MATERIALS AND METHODS: Mice were treated with ZAHE (100 and 200 mg/kg, p.o.) and imipramine (10 mg/kg injected i.p.) for 14 days. On 14th day of the treatment, depression-like behaviour was induced by LPS (0.83 mg/kg injected i.p.) and after 24 h of LPS administration, it was assessed by measuring behavioural parameters and biochemical estimations. RESULTS: Behavioural tests, including the open field test, forced swimming test, tail suspension test and sucrose preference test revealed that ZAHE (100 and 200 mg/kg, p.o.) and imipramine (10 mg/kg injected i.p.) alleviated the depression symptoms of LPS-induced mice. Moreover, ZAHE treatments reversed the LPS-induced alterations in the concentrations of norepinephrine and serotonin (5-HT) and inhibited the expression of brain-derived neurotrophic factor, pro-inflammatory cytokines and oxido-nitrosative stress in the mice. Acute toxicity was calculated to be LD50 > 2500 mg/kg. DISCUSSION AND CONCLUSIONS: This study showed that LPS-induced depression in mice was significantly prevented by ZAHE at both the dosages. In conclusion, ZAHE exhibited an antidepressant activity by altering monoaminergic neurotransmitters in the brain combined with its anti-inflammatory potential. Thus, it could be an effective therapeutic against inflammation-induced depression and other brain disorders.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Antidepressive Agents/pharmacology , Behavior, Animal/drug effects , Biogenic Monoamines/metabolism , Depression/prevention & control , Hippocampus/drug effects , Inflammation/prevention & control , Lipopolysaccharides , Plant Extracts/pharmacology , Zanthoxylum , Animals , Anti-Inflammatory Agents/isolation & purification , Anti-Inflammatory Agents/toxicity , Antidepressive Agents/isolation & purification , Antidepressive Agents/toxicity , Brain-Derived Neurotrophic Factor/metabolism , Cytokines/metabolism , Depression/chemically induced , Depression/metabolism , Depression/psychology , Disease Models, Animal , Eating/drug effects , Feeding Behavior/drug effects , Hexanes/chemistry , Hippocampus/metabolism , Hippocampus/physiopathology , Imipramine/pharmacology , Inflammation/chemically induced , Inflammation/metabolism , Inflammation/physiopathology , Inflammation Mediators/metabolism , Lethal Dose 50 , Male , Mice , Motor Activity/drug effects , Oxidative Stress/drug effects , Phytotherapy , Plant Extracts/isolation & purification , Plant Extracts/toxicity , Plants, Medicinal , Seeds , Solvents/chemistry , Zanthoxylum/chemistry , Zanthoxylum/toxicity
16.
Behav Brain Res ; 336: 99-110, 2018 01 15.
Article in English | MEDLINE | ID: mdl-28866130

ABSTRACT

Depression is commonly associated with hypothalamic-pituitary adrenal (HPA) axis dysfunction that primarily manifests as aberrant glucocorticoid secretion. Glucocorticoids act on Type I mineralocorticoid (MR) and Type II glucocorticoid receptors (GR) to modulate mood and endocrine responses. Successful antidepressant treatment normalizes HPA axis function, in part due to modulatory effects on MR and GR in cortico-limbic structures. Although women are twice as likely to suffer from depression, little is known about how antidepressants modulate brain, endocrine, and behavioral stress responses in females. Here, we assessed the impact of CORT118335 (GR modulator/MR antagonist) and imipramine (tricyclic antidepressant) on neuroendocrine and behavioral responses to restraint or forced swim stress (FST) in female rats (n=10-12/group). Increased immobility CORT118335 in the FST is purported to reflect passive coping or depression-like behavior. CORT118335 dampened adrenocorticotropic hormone (ACTH) and corticosterone responses to the FST, but did not affect immobility. Imipramine suppressed ACTH, but had minimal effects on corticosterone responses to FST. Despite these marginal effects, imipramine decreased immobility, suggesting antidepressant efficacy. In an effort to link brain-endocrine responses with behavior, c-Fos was assessed in HPA axis and mood modulatory regions in response to the FST. CORT118335 upregulated c-Fos expression in the paraventricular nucleus of the hypothalamus. Imipramine decreased c-Fos in the basolateral amygdala and hippocampus (CA1 and CA3), but increased c-Fos in the central amygdala. These data suggest the antidepressant-like (e.g., active coping) properties of imipramine may be due to widespread effects on cortico-limbic circuits that regulate emotional and cognitive processes.


Subject(s)
Imipramine/pharmacology , Stress, Physiological/drug effects , Thymine/analogs & derivatives , Adrenocorticotropic Hormone/pharmacology , Animals , Antidepressive Agents/pharmacology , Antidepressive Agents, Tricyclic/pharmacology , Behavior, Animal/physiology , Brain/metabolism , Corticosterone/metabolism , Depression/physiopathology , Depressive Disorder/physiopathology , Female , Hippocampus/metabolism , Hypothalamo-Hypophyseal System/metabolism , Hypothalamus/metabolism , Imipramine/metabolism , Mineralocorticoid Receptor Antagonists/metabolism , Mineralocorticoid Receptor Antagonists/pharmacology , Pituitary-Adrenal System/metabolism , Proto-Oncogene Proteins c-fos/metabolism , Rats , Rats, Sprague-Dawley , Receptors, Glucocorticoid/antagonists & inhibitors , Stress, Physiological/physiology , Stress, Psychological/physiopathology , Thymine/metabolism , Thymine/pharmacology
17.
Metab Brain Dis ; 33(2): 467-480, 2018 04.
Article in English | MEDLINE | ID: mdl-29101602

ABSTRACT

There is abundant evidence for both disorganized redox balance and cognitive deficits in major depressive disorder (MDD). Garcinia mangostana Linn (GM) has anti-oxidant activity. We studied the antidepressant-like and pro-cognitive effects of raw GM rind in Flinders Sensitive Line (FSL) rats, a genetic model of depression, following acute and chronic treatment compared to a reference antidepressant, imipramine (IMI). The chemical composition of the GM extract was analysed for levels of α- and γ-mangostin. The acute dose-dependent effects of GM (50, 150 and 200 mg/kg po), IMI (20 mg/kg po) and vehicle were determined in the forced swim test (FST) in FSL rats, versus Flinders Resistant Line (FRL) control rats. Locomotor testing was conducted using the open field test (OFT). Using the most effective dose above coupled with behavioral testing in the FST and cognitive assessment in the novel object recognition test (nORT), a fixed dose 14-day treatment study of GM was performed and compared to IMI- (20 mg/kg/day) and vehicle-treated animals. Chronic treated animals were also assessed with respect to frontal cortex and hippocampal monoamine levels and accumulation of malondialdehyde. FSL rats showed significant cognitive deficits and depressive-like behavior, with disordered cortico-hippocampal 5-hydroxyindole acetic acid (5-HIAA) and noradrenaline (NA), as well as elevated hippocampal lipid peroxidation. Acute and chronic IMI treatment evoked pronounced antidepressant-like effects. Raw GM extract contained 117 mg/g and 11 mg/g α- and γ-mangostin, respectively, with acute GM demonstrating antidepressant-like effects at 50 mg/kg/day. Chronic GM (50 mg/kg/d) displayed significant antidepressant- and pro-cognitive effects, while demonstrating parity with IMI. Both behavioral and monoamine assessments suggest a more prominent serotonergic action for GM as opposed to a noradrenergic action for IMI, while both IMI and GM reversed hippocampal lipid peroxidation in FSL animals. Concluding, FSL rats present with cognitive deficits and depressive-like behaviors that are reversed by acute and chronic GM treatment, similar to that of IMI.


Subject(s)
Behavior, Animal/drug effects , Depression/drug therapy , Garcinia mangostana/drug effects , Imipramine/pharmacology , Animals , Antidepressive Agents/pharmacology , Cognition/drug effects , Disease Models, Animal , Male , Motor Activity/drug effects , Rats
18.
Nutr Neurosci ; 21(4): 248-256, 2018 May.
Article in English | MEDLINE | ID: mdl-28102110

ABSTRACT

OBJECTIVES: The green seaweed Ulva sp. contains a large amount of ulvans, a family of sulphated polysaccharides. The present study was designed to investigate in rats the antidepressant- and anxiolytic-like effects of a hydrophilic extract of Ulva sp. (MSP) containing about 45% of ulvans. METHODS: After a 14-day administration of MSP at doses of 10, 20 and 40 mg/kg/day, 48 and 60 male adult Wistar rats were respectively tested in the elevated plus-maze (EPM) and the forced swimming test (FST). In the FST, MSP effects were compared to the reference antidepressant drug imipramine (IMI) (10 mg/kg/day). Acute and sub-chronic toxicities of the extract were also assessed in male and female rats following OECD guidelines. RESULTS: MSP treatment did not modify anxiety-related behaviour in the EPM. In contrast, MSP induced a dose-dependent reduction of immobility behaviour in the FST. At the highest tested dose of 40 mg/kg, MSP displayed a significant antidepressant-like effect similar to IMI. MSP did not modify the exploratory behaviour of rats in the open field test and did not produce any toxic effect. DISCUSSION: MSP may potentially represent a good adjunct or alternative to existing antidepressant therapeutics. Further studies are necessary to confirm the mechanism of action of MSP and its modulation of brain functioning.


Subject(s)
Anti-Anxiety Agents/pharmacology , Antidepressive Agents/pharmacology , Plant Extracts/pharmacology , Ulva/chemistry , Animals , Anti-Anxiety Agents/administration & dosage , Anti-Anxiety Agents/toxicity , Antidepressive Agents/administration & dosage , Antidepressive Agents/toxicity , Behavior, Animal/drug effects , Dose-Response Relationship, Drug , Exploratory Behavior/drug effects , Female , Imipramine/pharmacology , Male , Plant Extracts/administration & dosage , Plant Extracts/toxicity , Rats , Rats, Wistar , Swimming , Toxicity Tests, Acute , Toxicity Tests, Subchronic
19.
J Psychiatr Res ; 94: 29-35, 2017 11.
Article in English | MEDLINE | ID: mdl-28647678

ABSTRACT

Depression is a recurrent neuropsychiatric disorder that affects millions of individuals worldwide and impact negatively on the patients' social functions and quality of life. Studies have shown that i.p injection of lipopolysaccharide (LPS) induces depressive-like behavior in rodents via induction of oxidative stress and neuroinflammation. Methyl jasmonate (MJ), an isolated compound from jasmine plant has gained reputation in aromatherapy for treatment of depression, nervousness and memory deficits. This study was designed to evaluate the effects of MJ on LPS-induced depressive-like behavior in mice. Mice were given MJ (5-20 mg/kg), imipramine (10 mg/kg) or vehicle (10 mL/kg) intraperitoneally for 7 consecutive days. On day 7, treatment was carried out 30 min prior to i.p injection of LPS (830 µg/kg). Twenty four hours after LPS administration, tail suspension, forced swim and sucrose preference tests were carried out. Thereafter, serum corticosterone levels were determined using ELISA. The levels of malondialdehyde (MDA), glutathione (GSH) and tumor necrosis factor-alpha (TNF-α) were determined in brain tissue homogenates. LPS significantly increased immobility time in the tail suspension and forced swim tests when compared with vehicle (p < 0.05), which indicates depressive-like syndromes. However, the increased immobility time was significantly reduced by MJ (5-20 mg/kg) when compared with LPS-treated group. LPS administration also altered the levels of MDA, GSH, corticosterone and TNF alpha in mice, which was significantly reversed by MJ. These findings suggest that attenuation of LPS-induced depressive-like behavior by MJ may be related to suppression of oxidative stress and release of TNF alpha.


Subject(s)
Acetates/pharmacology , Antidepressive Agents/pharmacology , Behavior, Animal/drug effects , Brain/drug effects , Corticosterone/blood , Cyclopentanes/pharmacology , Depression/drug therapy , Depression/metabolism , Jasminum , Lipopolysaccharides/pharmacology , Oxidative Stress/drug effects , Oxylipins/pharmacology , Plant Extracts/pharmacology , Tumor Necrosis Factor-alpha/drug effects , Acetates/administration & dosage , Animals , Antidepressive Agents/administration & dosage , Antidepressive Agents, Tricyclic/pharmacology , Cyclopentanes/administration & dosage , Depression/blood , Depression/chemically induced , Disease Models, Animal , Imipramine/pharmacology , Infusions, Parenteral , Male , Mice , Oxylipins/administration & dosage , Plant Extracts/administration & dosage
20.
Naunyn Schmiedebergs Arch Pharmacol ; 390(8): 769-774, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28429110

ABSTRACT

Hyperactivity of the hypothalamic-pituitary-adrenal axis (HPA) and impairment of the central corticotropin-releasing factor (CRF) system are factors in the pathogenesis of depression. Though several antagonists of the CRF1 receptor were effective in the recognized behavioral tests for antidepressant activity, there is still little information on the potential interactions between CRF1 receptor inhibitors and conventional antidepressant therapy. The aim of our study was to assess the influence of SN003, a CRF1 receptor blocker, on the activity of imipramine and fluoxetine in the forced swim test (FST) in rats which presented some signs of depression. The experiments were carried out on female Wistar rats subjected to 14-day subcutaneous corticosterone (CORT) administration (20 mg/kg/day). The antidepressant-like effect was determined by the FST and the CRF levels in the hypothalamus, amygdala, and peripheral blood were measured by a high-sensitivity immunoenzymatic test. SN003 (0.5 mg/kg) potentiated the antidepressant-like effect of imipramine (15 mg/kg) and fluoxetine (7.5 mg/kg). Moreover, the co-administration of the tested agents abolished CORT-induced increase in CRF levels in the examined biological material more profoundly than monotherapy. Our present findings give further evidence that the blockage of CRF action may be useful in the treatment of mood disorders. The concurrent use of well-known antidepressants with CRF1 receptor antagonists could be beneficial in terms of safety, since it requires lower doses of the applied agents.


Subject(s)
Antidepressive Agents/therapeutic use , Corticosterone/pharmacology , Depression/drug therapy , Receptors, Corticotropin-Releasing Hormone/antagonists & inhibitors , Amygdala/drug effects , Amygdala/metabolism , Animals , Antidepressive Agents/pharmacology , Behavior, Animal/drug effects , Corticotropin-Releasing Hormone/blood , Corticotropin-Releasing Hormone/metabolism , Depression/metabolism , Drug Therapy, Combination , Female , Fluoxetine/pharmacology , Fluoxetine/therapeutic use , Hypothalamus/drug effects , Hypothalamus/metabolism , Imipramine/pharmacology , Imipramine/therapeutic use , Locomotion/drug effects , Pyridines/pharmacology , Pyridines/therapeutic use , Rats, Wistar , Receptors, Corticotropin-Releasing Hormone/metabolism , Swimming , Triazoles/pharmacology , Triazoles/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL